PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE)-- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, ...
PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels FDA feedback from recent ...
Discover HTML's role in web content display and navigation. Learn about its foundational functions, evolution, and ...
Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers SAN ...
Discover historical prices for MBIO stock on Yahoo Finance. View daily, weekly or monthly format back to when Mustang Bio, Inc. stock was issued.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results